Table 1.

Demographics^a

	Afatinib group (N = 224)	Osimertinib group (N = 326)	P value
Age (years), mean	68.82	70.14	0.152
Sex
Male/Female	105/119	133/193	0.162
Smoking status
Never/former or current/unknown	111/107/6	185/137/4	0.153
Clinical stage (8th edition TNM stage classification)
1-2/3/4/R	5/25/152/42	10/24/228/64	0.469
Histologic subtypeb
ADC	215	313	1
SCC	5	7	1
Other	5	6	0.765
EGFR mutationb
Ex19del	114	163	0.862
L858R	74	155	0.001
Uncommon	39	9	<0.001
ECOG PS
0/1/2 or more/Unknown	67/124/30/3	114/159/47/6	0.328
Pleural effusion
Yes	65	114	0.165
Brain metastasis
Yes	75	85	0.07
PD-L1
<1/1-49/50≤/Unknown	53/56/41/74	102/79/55/90	0.233

ADC, adenocarcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; PD-L1, programmed death-ligand 1; SCC, squamous cell carcinoma.

^aEarly-stage patients received EGFR-TKI therapy in first-line settings due to intolerability for operation or radiation therapy resulting from factors such as advanced age or poor PS.

^bThe cases with multiple factors were counted in each group of the categories of Histologic subtype and EGFR mutation.